About this episode
Dr Rebecca Haberman from the Department of Medicine, Division of Rheumatology, New York University Grossman School of Medicine and Psoriatic Arthritis Center, USA. In this edition Dr Haberman disucsses her recent paper ‘Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial.’
Get every episode summarized
Each time The IMID Forum publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The IMID Forum
Author Interview: Doctor Elise van Mulligen, September 2026
The IMID Forum
Sep 3, 202621:20pending
Discussing RA: Biologic effectiveness and treatment persistence in RA
The IMID Forum
Aug 27, 20268:52pending
Discussing PsA: Advances in Psoriatic Arthritis Management and Treatment Safety
The IMID Forum
Aug 20, 202624:22pending
Author Interview: Professor Axel Finckh and Associate Professor Bente Glintborg,...
The IMID Forum
Aug 13, 202626:58pending